Cutting Edge Technology to Enhance Mental Health Treatment

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, April 13, 2023

With a combination of innovative technologies and neurological experience this firm stands out in the bioscience market. And a targeted drug delivery to the brain compound efficacy can be enhanced while mitigating side effects.

Psycheceutical Bioscience, Inc (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review's Top 10 Biotech Startups for 2023 . Psycheceutical earned recognition for its significant progress in developing innovative patented delivery technologies that are intended to increase the safety and efficacy of psychedelic compounds.

The firm develops cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases.

Shares were trading at $0.1096 in morning trade.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.